Parabolic Drugs, incorporated on Feb. 22, 1996, is an active pharmaceutical ingredient (API) and API intermediates company based in India. Operating with a business model covering the API & API intermediates segment, the company offers a product basket of over 31 products including semi-synthetic oral penicillin and oral cephalosporin. In FY07, commercial production of sterile bulk drugs, amorphous and cefixime was initiated and new fourth generation cephlosprins orals and sterile products were launched. The manufacturing plant in Derabassi has an installed capacity of 127.4 MT. The facility has registered its various products in Eastern Europe and Russia. A sterile facility for both, semi-synthetic penicillin and semi-synthetic cephalosporin have already been set up in the existing Derabassi site to cater the demand initially of the non regulated market and after filings in the regulated market. The other unit located at Panchkula close to Chandigarh in Haryana is a manufacturing facility for 6- Amino Penicillanic Acid, which has been approved to deliver product to Ranbaxy and supply to the regulatory market. It has been approved by USFDA for supplies to US markets. Laboratories established by the company are well equipped with the latest equipment and manned by a set of qualified professionals. In FY07, the company started construction of a new R & D center at Barwala. It is a preferred supplier to some of the leading pharmaceutical companies in India including Ranbaxy Laboratories, Alkem Laboratories, Aristro Pharmaceutials, Cipla, FDC, Lyka Labs, and DSM among others. It has already penetrated the East Asian, North European, Chinese, Brazilian, Mexican and other Latin American Markets which generate 60% of sales. It has also entered into an agreement with the Ranbaxy Laboratories to manufacture 6APA. The registered office is at SCO 99 100, Level 4, Sector 17-B, Chandigarh-160017, India.
You
should Trade Less But Trade Accurately & this is Achieved with our Tip.
